Medicina (Kaunas, Lithuania)

GLP1's role in body weight and blood sugar control in people with diabetes

Updated

Abstract

Semaglutide may lead to superior outcomes in weight management and cardiovascular health compared to other diabetes medications.

  • GLP-1 receptor agonists (GLP-1 RAs) can influence weight management and cardiovascular health in diabetic patients.
  • Dulaglutide and semaglutide are highlighted for their effects on body weight and cardiovascular disease management.
  • Semaglutide is associated with improved blood sugar control, reduced body weight, and lower cardio-metabolic risk factors in individuals with type 2 diabetes.
  • GLP-1 RAs may provide cardiovascular protection by affecting factors such as blood pressure and glycated hemoglobin (HbA1c) levels.
  • The 4GI model offers a new approach to evaluate the interactions of various medications in diabetes treatment.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free